跳至主要内容
临床试验/ACTRN12616001188426
ACTRN12616001188426终止4 期

A double blind, randoMIsed controlled cliNical trIal comparing the effect of treatment with oral MRA (spironolactone) versus placebo on the frequency and duration of atrIal fibrillation in patients with an implanted cardiac device in New Zealand: MINIMIZE-AF

niversity of Otago0 个研究点目标入组 150 人开始时间: 2016年8月30日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
19 Years 至 o limit(—)
性别
All

入选标准

  • Patients with an implanted cardiac device capable of recording the frequency and duration of AF events and with
  • evidence of AF or AHRE within the 6months
  • prior to recruitment will be eligible.
  • age >18 years (without childbearing
  • potential for women); with an implantable device capable of
  • AF or AHRE monitoring; and with device documented AF or AHRE (defined as AHRE >220 bpm for >2% of the time
  • or for > 5mins on at least one occasion) in the last 6months.

排除标准

  • Permanent AF,
  • Receiving AF suppression pacing
  • History of heart failure with indication for MRAs
  • A clinical indication for MRA or K+ sparing diuretic
  • Contraindication to MRA
  • Severe renal dysfunction
  • Sustained hyperkalaemia in the absence of reversible cause

研究者

相似试验